Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma has announced groundbreaking research indicating that its drug Namodenoson exhibits anti-cancer and liver-protective effects by increasing the production of the beneficial cytokine adiponectin. These findings will be shared at an upcoming international drug discovery conference. Currently, Namodenoson is under advanced clinical testing, with a pivotal Phase III study for liver cancer and a Phase IIb study for MASH, showing promise as a safe treatment option.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
